trending Market Intelligence /marketintelligence/en/news-insights/trending/H1ac-UbglsbLtw-WU4zzjg2 content esgSubNav
In This List

Teva, BioDelivery reach settlement over opioid addiction drug

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Teva, BioDelivery reach settlement over opioid addiction drug

Teva Pharmaceutical Industries Ltd. agreed not to sell a generic version of BioDelivery Sciences International Inc.'s opioid addiction treatment as part of a settlement to end a patent litigation against the company.

Teva is barred from marketing a generic version of Bunavail until July 23, 2028.

BioDelivery filed a lawsuit in the U.S. District Court for the District of Delaware after Teva filed an application seeking approval from the U.S. Food and Drug Administration to market a generic version of the drug.

BioDelivery said the abbreviated new drug application infringed on several of its patents.